Merck has signed an agreement for Santen Pharmaceutical to purchase Merck's ophthalmology products, Cosopt (dorzolamide hydrochloride+timolol maleate ophthalmic solution), Cosopt PF (dorzolamide hydrochloride+timolol maleate ophthalmic solution) 2%/0.5%, Trusopt (dorzolamide hydrochloride ophthalmic solution) sterile ophthalmic solution 2%, Trusopt PF (dorzolamide hydrochloride ophthalmic solution) preservative-free, Timoptic (timolol maleate ophthalmic solution), Timoptic PF (timolol maleate preservative free ophthalmic solution in unit dose dispenser), Timoptic XE (timolol maleate ophthalmic gel forming solution), Saflutan (tafluprost) and Taptiqom (tafluprost+timolol maleate ophthalmic solution, in development) in Japan and key markets in Europe and Asia Pacific.
Santen will make an up-front payment of approximately USD600mn and additional payments based on defined sales milestones as needed. The annual sales of these ophthalmology products in the markets within the scope of the agreement are approximately USD400mn. Santen will also purchase supply of the ophthalmology products covered by this agreement from Merck for a two- to five-year period. The agreement is subject to certain closing conditions, including obtaining antitrust clearance in Japan and other closing conditions related to specific markets or regions. The agreement is expected to close in most markets in a few months.
Merck divested its US ophthalmology business to Akorn Pharmaceuticals in 2013 and 2014. Merck will continue to sell its ophthalmology products in Latin America, Canada, Australia, the Middle East, Africa and other markets.
|Companies Involved||Merck, Santen Pharmaceutical|
|Date Last Reported|
|Agreement Type||Commercialisation, Distribution|
|Estimated Total Value||>USD600mn|
|Investment To Date||USD600mn|
|Therapeutic Area||Sensory Organs|